On March 14, 2018 Mar. 14, 2018– ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting to be held from April 14-18, 2018 in Chicago (Press release, ImmunoGen, MAR 14, 2018, View Source [SID1234524769]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"ImmunoGen has in-depth expertise in all aspects of ADCs, which has resulted in the most comprehensive toolbox of ADC technologies in the industry," said Richard Gregory, Ph.D., ImmunoGen’s chief scientific officer. "The data to be presented at AACR (Free AACR Whitepaper) further build on our leadership position in the space and demonstrate continued innovation, including further advancements to payloads and targets for anti-tumor activity, as well as insights into factors that determine the clinical efficacy of ADCs."

Details of ImmunoGen’s poster presentations are as follows:

Title: "A new class of DNA alkylating indolino-benzodiazepine agents (BIAs) linked with a DNA binding moiety for use with antibody-drug conjugates (ADCs)" (abstract #747)
Date:April 15, 2018
Time: 1:00 – 5:00pm CT

A new class of DNA alkylating effector molecules for use in ADC development in which an IGN (indolino-benzodiazepine) monomer subunit is connected to a DNA binding moiety (e.g., Bi-Aryl, or Bis-Aryl) are termed BIAs. BIA ADCs displayed potent, antigen-specific in vitro activity across a panel of FRα-expressing cell lines. In vivo, these ADCs demonstrated potent efficacy in xenograft models at doses well below the maximum tolerated dose.
Title: "Development of an in vivo model system to assess the interplay between the various drivers of antibody drug conjugate (ADC) activity" (abstract #753)
Date:April 15, 2018
Time: 1:00 – 5:00pm CT

To better understand the variables that impact ADC pharmacokinetics, tolerability, bio-distribution, and efficacy, a novel, cross-reactive model system was created. An anti-murine folate receptor alpha (FRα) antibody was generated that binds to both mouse and human FRα. The model system allows experiments to be designed in a cross-reactive system to examine how modifications to the antibody, linker or cytotoxic payload impact safety, and efficacy.
Title: "Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates" (abstract #2900)
Date:April 16, 2018
Time: 1:00 – 5:00pm CT

Endoglin/CD105 is a well-acknowledged endothelial cell proliferation marker, which is strongly expressed in tumor-associated vasculature. It was evaluated as an oncology target using ADCs of an anti-CD105 antibody with potent anti-microtubule maytansinoids DM1 and DM4, and the highly potent IGN DNA-alkylating payload, DGN549. Endoglin targeted huRH105-DM and huRH105-DGN549 conjugates produced modest anti-tumor activity and therapeutic indices in rat models.
Additional information and full abstracts can be found at www.aacr.org.